Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
Oxford, UK - March 17, 2026. Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today ...
We owe a lot to tissue resident memory T cells (T RM). These specialized immune cells are among the body's first responders to disease. Rather than coursing through the bloodstream-as many T cells ...
A new start-up is launching out of Shanghai with $68.7 million and a plan to tackle cancer and autoimmune diseases with ...
The Notch signaling pathway plays a pivotal role in determining cell fate, especially in the development and function of T cells. But mimicking this highly mechanical, contact-dependent pathway in the ...
A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
The US Food and Drug Administration’s (FDA) guidance documents offer sponsors greater clarity on trial designs and control strategies that could potentially accelerate the development of in vivo CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results